C-C Chemokine Receptor Type 4 Market Report 2025

The C-C chemokine receptor type 4 market size has grown strongly in recent years. It will grow from $1.14 billion in 2024 to $1.25 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. Growth in the historic period was driven by increasing demand for personalized medicine, greater understanding of CCR4’s role in disease pathways, heightened focus on targeted cancer therapies, and rising global healthcare expenditure.

The C-C chemokine receptor type 4 market size is expected to see strong growth in the next few years. It will grow to $1.79 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. Growth in the forecast period is expected to result from increased investment in biologics and biosimilars, growing demand for novel immunotherapy approaches, expanded access to healthcare facilities in emerging markets, stronger focus on minimizing side effects of existing treatments, and broader use of digital health tools for patient monitoring. Key trends anticipated for the forecast period include advancements in drug delivery systems, development of advanced biotechnological methods, creation of novel immunotherapies, innovation in biomarker identification, and progress in digital transformation.

The increasing adoption of personalized medicine is expected to drive the growth of the C-C chemokine receptor type 4 (CCR4) market in the future. Personalized medicine tailors treatment and prevention strategies to an individual's genetic makeup, lifestyle, and environmental factors. The demand for this approach is growing as advancements in genetic testing and data analytics enable more accurate and effective treatments, minimizing trial-and-error methods and enhancing patient outcomes. As personalized medicine gains traction, there is a greater need for CCR4-targeting therapies, as these can be specifically designed to address a patient’s unique cancer or immune system characteristics, ensuring more effective treatment. For instance, in February 2024, the Personalized Medicine Coalition (PMC), a U.S.-based nonprofit organization, reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, compared to just six in 2022. This rise in personalized medicine adoption is a key driver for the growth of the CCR4 market.

Companies in the CCR4 market are focusing on developing advanced solutions such as humanized monoclonal antibodies (mAb) to enhance therapeutic specificity, improve patient safety, and address unmet needs in oncology and inflammatory diseases. Humanized monoclonal antibodies are lab-engineered antibodies derived from non-human species and modified to resemble human antibodies more closely. This reduces the risk of immune rejection while targeting specific antigens for treatment. For example, in June 2022, Kyowa Kirin Inc., a Japanese biopharmaceutical company, received a Notice of Compliance from Health Canada for POTELIGEO (mogamulizumab) for adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) who had undergone at least one prior systemic therapy. POTELIGEO is a humanized monoclonal antibody targeting CCR4, a protein found on malignant T-cells, and is produced using Kyowa Kirin’s proprietary POTELLIGENT platform, which enhances the therapeutic efficacy through antibody-dependent cellular cytotoxicity.

In October 2022, Amgen Inc., a U.S.-based biopharmaceutical company, acquired ChemoCentryx Inc. for $3.7 billion, strengthening its position in inflammation and nephrology therapies. Through this acquisition, Amgen expanded its portfolio with TAVNEOS, a first-in-class treatment for ANCA-associated vasculitis, and gained access to ChemoCentryx’s expertise in small molecule inhibitors, including a preclinical CCR4 antagonist and other chemokine receptor antagonists. This move is expected to enhance Amgen’s ability to serve patients with serious diseases.

Major players in the c-c chemokine receptor type 4 market are Pfizer Inc., Merck & Co. Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., GlaxoSmithKline plc (GSK), Amgen Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Ono Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., RAPT Therapeutics Inc., Abcam Plc, R&D Systems Inc., Sino Biological Inc., CUSABIO Technology LLC, Aurigene Oncology Limited, Creative Biolabs Inc., MyBioSource Inc., Multispan Inc., and Shanghai Meiyue Biotech Development Co. Ltd.

North America was the largest region in the C-C chemokine receptor type 4 market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in C-C chemokine receptor type 4 report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the C-C chemokine receptor type 4 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

C-C chemokine receptor type 4 (CCR4) is a protein located on the surface of certain immune cells, including T helper 2 cells and regulatory T cells. It interacts with specific chemokines such as CCL17 and CCL22 to direct immune cell migration to sites of inflammation or lymphoid tissues. CCR4 is involved in immune regulation, allergic responses, and cancer progression, making it an important therapeutic target in multiple diseases.

The main product categories of CCR4 include monoclonal antibodies, small molecule inhibitors, peptide-based therapeutics, and combination therapy products. CCR4 monoclonal antibodies are laboratory-engineered antibodies designed to bind specifically to the CCR4 receptor on immune cells to modulate immune system activity for therapeutic purposes. These treatments are delivered through injectables, oral tablets, topical formulations, and nasal sprays, with applications in immunology, central nervous system disorders, mycosis fungoides, and other conditions. End users include pharmaceutical companies, biotechnology firms, research institutions, contract research organizations, and hospitals and clinics.

The C-C chemokine receptor type 4 market research report is one of a series of new reports that provides C-C chemokine receptor type 4 market statistics, including C-C chemokine receptor type 4 industry global market size, regional shares, competitors with a C-C chemokine receptor type 4 market share, detailed C-C chemokine receptor type 4 market segments, market trends and opportunities, and any further data you may need to thrive in the C-C chemokine receptor type 4 industry. This C-C chemokine receptor type 4 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The C-C chemokine receptor type 4 market consists of sales of diagnostic assay kits, flow cytometry reagents, ELISA detection kits, gene expression assays, and immunotherapy vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.